Loading
A phase 1/2 trial of SNB-101 in small-cell lung cancer, run by SN BioScience, now recruiting.
SNB-101 for Treatment of Extensive Stage Small Cell Lung Cancer is a phase 1/2 interventional study registered as NCT07391813 by SN BioScience, with 55 participants planned, started 2026-03 and due to reach its primary completion in 2028-12. Interventions recorded: SNB-101.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Extensive-stage small-cell lung cancer, Small-cell lung cancer and the tag pipeline.
Shares Small-cell lung cancer and the tag pipeline.
Shares Small-cell lung cancer and the tag pipeline.
Shares Extensive-stage small-cell lung cancer, Small-cell lung cancer and the tag pipeline.
Shares Extensive-stage small-cell lung cancer, Small-cell lung cancer and the tag pipeline.
Shares Extensive-stage small-cell lung cancer, Small-cell lung cancer and the tag pipeline.
Shares Extensive-stage small-cell lung cancer, Small-cell lung cancer and the tag pipeline.
Shares Extensive-stage small-cell lung cancer, Small-cell lung cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/